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McMahon GE, Stebbings GK, Neale JPH, Lockey SJ, Ribbans WJ,
Cook CJ, Vance B, Raleigh SM, Roberts C, Bennett MA, Wang G,
Collins M, Pitsiladis YP, Williams AG. Association of ACTN3 R577X but
not ACE I/D gene variants with elite rugby union player status and playing
position. Physiol Genomics 48: 196–201, 2016. First published January 12,
2016; doi:10.1152/physiolgenomics.00107.2015.—We aimed to quantify
the ACE I/D and ACTN3 R577X (rs1815739) genetic variants in elite
rugby athletes (rugby union and league) and compare genotype frequen-
cies to controls and between playing positions. The rugby athlete cohort
consisted of 507 Caucasian men, including 431 rugby union athletes that
for some analyses were divided into backs and forwards and into specific
positional groups: front five, back row, half backs, centers, and back
three. Controls were 710 Caucasian men and women. Real-time PCR of
genomic DNA was used to determine genotypes using TaqMan probes
and groups were compared using 2 and odds ratio (OR) statistics.
Correction of P values for multiple comparisons was according to
Benjamini-Hochberg. There was no difference in ACE I/D genotype
between groups. ACTN3 XX genotype tended to be underrepresented in
rugby union backs (15.7%) compared with forwards (24.8%, P  0.06).
Interestingly, the 69 back three players (wings and full backs) in rugby
union included only six XX genotype individuals (8.7%), with the R
allele more common in the back three (68.8%) than controls (58.0%;
2  6.672, P  0.04; OR  1.60) and forwards (47.5%; 2  11.768,
P  0.01; OR  2.00). Association of ACTN3 R577X with playing
position in elite rugby union athletes suggests inherited fatigue resistance
is more prevalent in forwards, while inherited sprint ability is more
prevalent in backs, especially wings and full backs. These results also
demonstrate the advantage of focusing genetic studies on a large cohort
within a single sport, especially when intrasport positional differences
exist, instead of combining several sports with varied demands and
athlete characteristics.
-actinin-3; angiotensin converting enzyme; athlete genetics; Rugby-
Gene project
RUGBY IS AN INTERMITTENT TEAM sport comprising two similar
but differing codes, rugby league (RL) and rugby union (RU).
Both codes consist of diverse playing positions, each with
different physiological, anthropometric, and technical attri-
butes (8, 10, 20, 27) including two distinct subgroups in each
code: forwards and backs. Recently, global positioning system
tracking and time-motion analysis have been used to estimate
the physical demands of rugby athletes and compare forwards
and backs during high-level match play (8, 20, 27). In RU,
backs travelled 12% greater total distance (6,545 m vs. 5,850
m), achieved maximum speeds 16% faster (30.4 km/h vs. 26.3
km/h) and engaged in over four times (58% vs. 13%) high-
intensity running activities (5.0 m/s), as a proportion of total
activity (8, 27) compared with forwards. These data suggest a
more sprint-oriented metabolic demand in backs compared
with forwards. Furthermore, due to the complexities of forward
play, forwards performed sixfold more (9.9%) high-intensity
static exertion activities (rucks, mauls, scrums, and line-outs)
than backs (1.6%) and spent 19.8% more time running above
80% of their maximal speed (8, 27, respectively). This implies
that forwards, although often of higher body mass (14), are
more likely to benefit from fatigue-resistant physiological
qualities than backs. Accordingly, Deutsch et al. (10) showed
that forwards had a notably higher work-to-rest ratio than
backs (1:7 and 1:22, respectively). Given that the roles of backs
and forwards differ significantly in terms of physiological
demands, these differences may be reflected in distinct genetic
characteristics (18). Elite RL athletes cover similar total dis-
tances (7,000 m vs. 5,000 m; backs vs. forwards, respec-
tively) and have similar anthropometric characteristics to RU
athletes (20). Players regularly transfer between RL and RU
codes so investigating both codes (combined and separately)
for their genetic characteristics is justified.
The two most studied gene variants in exercise genomics
(ACE I/D and ACTN3 R577X polymorphisms) have recently
been considered in meta-analyses. Ma et al. (23) reported that
ACE II genotype was associated with physical performance
[odds ratio (OR) 1.23], especially endurance performance (OR
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1.35). Furthermore, ACTN3 RR genotype was associated with
speed and power performance (OR 1.21; 23), supported else-
where (2). More extensive information regarding ACE I/D and
ACTN3 R577X polymorphisms is available (13, 26). Due to
differences in physical characteristics between rugby athletes
and the general population and the diverse physiological de-
mands within rugby, these genetic markers could predispose
athletes to success or specific roles at the elite level.
One recent paper examined ACE I/D genotype frequency
distribution in young, nonelite RU athletes. ACE I/D genotype
frequencies did not differ between forwards and backs, with no
control group included (5). The same group (4) also investi-
gated ACTN3 R577X in 102 young male RU athletes and
reported no association, despite some tendencies for the R
allele to be more frequent in backs or subgroups of backs.
Studying elite athletes would be better able to answer the
question whether these genetic variants are associated with
elite status and playing position in rugby.
Therefore, the purpose of the present study was to investi-
gate whether elite rugby athletes in the RugbyGene project (18)
and a control group differed in terms of ACE I/D and ACTN3
R577X genotype distribution and whether athletes in special-
ized playing positions similarly differed. It was hypothesized
that the ACTN3 R allele and the ACE I allele would be more
frequent in rugby athletes than controls. It was further hypoth-
esized that ACTN3 XX and ACE II genotypes would be
underrepresented in RU backs compared with forwards, due to
differences in overall work-to-rest ratio and differing require-
ments for high maximum speed.
METHODS
Participants
Ethical approval was granted by Manchester Metropolitan Univer-
sity (MMU), University of Glasgow, University of Cape Town, and
Northampton University ethics committees, and the study complies
with the Declaration of Helsinki. As part of the RugbyGene project,
elite Caucasian male rugby athletes [n  507; mean (standard devi-
ation) height 1.85 (0.07) m, mass 101 (14) kg, age 29 (7) yr] including
71.2% British, 17.2% South African, 7.1% Irish, and 4.5% of other
nationalities were recruited, having given written informed consent.
Caucasian controls [61% male; n  710; height 1.73 (0.10) m, mass
74 (13) kg, age 29 (16) yr] included 89.6% British, 8.9% South
African, 0.7% Irish, and 0.8% of other nationalities. Athletes were
considered elite if they had competed regularly (5 matches) since
1995 in the highest professional league in the UK, Ireland, or South
Africa for RU and the highest professional league in the UK for RL. Of
the RU athletes, 53.4% had competed at international level for a “High
Performance Union” (Regulation 16, http://www.worldrugby.org), and
38.5% of RL had competed at international level. International status was
confirmed as of 1 January 2015. Athletes were taller and heavier (P 
0.0005) but not older (P  0.871) than controls.
Procedures
Sample collection. Blood (70% of all samples), saliva (25%),
or buccal swab samples (5%) were obtained via the following
protocols. Blood was drawn from a superficial forearm vein into an
EDTA tube and stored in sterile tubes at 20°C until processing.
Saliva samples were collected into Oragene DNA OG-500 collection
tubes (DNA Genotek, Ottawa, Ontario, Canada) according to the
manufacturer’s protocol and stored at room temperature until process-
ing. Sterile buccal swabs (Omni swab; Whatman, Springfield Mill,
UK) were rubbed against the buccal mucosa of the cheek for 30 s.
Tips were ejected into sterile tubes and stored at 20°C until pro-
cessing.
DNA isolation and genotyping. DNA isolation and genotyping
were performed in the MMU, University of Glasgow, University of
Cape Town (DNA isolation only), and University of Northampton
laboratories. There are some differences between protocols summa-
rized below; however, there was 100% agreement among reference
samples genotyped in the three genotyping centers, i.e., Glasgow,
Northampton, and MMU laboratories. The majority of samples were
processed and genotyped in the MMU laboratory. Genotype calling
was successful for both variants in all samples.
At MMU and Glasgow, DNA isolation was performed with the
QIAamp DNA Blood Mini kit and standard spin column protocol,
following the manufacturer’s instructions (Qiagen, West Sussex, UK).
Briefly, 200 	l of whole blood/saliva, or one buccal swab, was lysed
and incubated, the DNA washed, and the eluate containing isolated
DNA stored at 4°C. In Cape Town, DNA was isolated from whole
blood by a different protocol (22). In brief, samples were lysed and
centrifuged, the DNA washed, and samples stored at 20°C. Geno-
typing of DNA isolated in Cape Town was performed in Glasgow. At
Northampton, DNA was isolated from whole blood with Flexigene
kits (Qiagen). In brief, samples were lysed, and DNA precipitated and
washed, with samples stored at 20°C.
Genotyping. Genotyping in the Glasgow laboratory was performed
on ACTN3 (rs1815739) and an ACE tag single nucleotide polymor-
phism (SNP) (rs4341) in perfect linkage disequilibrium with ACE I/D
in Caucasians (15). In brief, 10 	l Genotyping Master Mix (Applied
Biosystems, Paisley, UK), 1 	l SNP-specific TaqMan assay (Applied
Biosystems), 6 	l nuclease-free H2O, and 3 	l DNA solution (9 ng
DNA) were added per well. In the Northampton laboratory, genotyp-
ing was performed for ACTN3 R577X (rs1815739) by combining 10
	l of Genotyping Master Mix, 8 	l H2O, 1 	l assay mix with 1 	l of
purified DNA (10 ng). In both laboratories, PCR was performed
using a StepOnePlus real-time detector (Applied Biosystems). In
brief, denaturation began at 95°C for 10 min, with 40 cycles of
incubation at 92°C for 15 s then annealing and extension at 60°C for
1 min. Initial analysis was performed using StepOnePlus software
version 2.3 (Applied Biosystems). There was 100% agreement within
duplicates of all samples.
At MMU, samples were genotyped for ACTN3 R577X (rs1815739)
by combining 5 	l Genotyping Master Mix, 4.3 	l H2O, 0.5 	l assay
mix, and 0.2 	l of purified DNA (9 ng), for samples derived from
blood and saliva. For DNA derived from buccal swabs, 5 	l Geno-
typing Master Mix was combined with 3.5 	l H2O, 0.5 	l assay mix,
and 1 	l DNA solution (9 ng DNA). Either a Chromo4 real-time
system (Bio-Rad, Hertfordshire, UK) or a StepOnePlus was used. In
brief, denaturation began at 95°C for 10 min, with 40 cycles of
incubation at 92°C for 15 s and then annealing and extension at 60°C
for 1 min. Initial genotyping analysis was performed with Opticon
Monitor software version 3.1 (Bio-Rad) or StepOnePlus software
version 2.3. Duplicates of all samples were in 100% agreement. For
ACE I/D at MMU, 5 	l of Genotyping Master Mix, 1.55 	l H2O, 0.9
	l of I and D allele-specific probes, and 0.38 	l of ACE primer 111,
112, and 113 (sequences below) were combined with 0.5 	l DNA
solution (23 ng DNA) per well for blood and saliva. For DNA
derived from buccal cells, primer and probe volumes were identical,
but 0.05 	l H2O and 2 	l DNA solution (18 ng DNA) were used.
Similarly, in the Northampton laboratory, ACE I/D was genotyped by
combining 11 	l of Genotyping Master Mix, 2 	l of I and D probes,
2 	l of ACE primer 111, 112, 113, and 4 	l DNA solution (40 ng
DNA). Either a Chromo4 real-time system or a StepOnePlus was
used. In brief, there were 50 cycles of denaturation at 92°C for 15 s
and then annealing and extension at 57°C for 1 min. Initial analysis
was performed with Opticon Monitor 3.1 software or StepOnePlus
software version 2.3. Again, there was 100% agreement within du-
plicates of all samples.
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Primers and probes. For rs1815739 and rs4341, the appropriate
TaqMan assay was used (Applied Biosystems). For the direct ACE I/D
assay, three primers (150 nM each) and probes (VIC, 150 nM and FAM,
75 nM; 21) were used: primer ACE111, 5=-CCCATCCTTTCTC-
CCATTTCTC-3=; primer ACE112, 5=-AGCTGGAATAAAATTGGC-
GAAAC-3=; primer ACE113, 5=-CCTCCCAAAGTGCTGGGATTA-3=;
I allele-specific probe (VIC-ACE100), VIC-5=-AGGCGTGATA-
CAGTCA-3=-MGB; D allele-specific probe (FAM-ACE100), FAM-5=-
TGCTGCCTATACAGTCA-3=-MGB.
Positional Groups
To assess genotype and allele frequencies within the RU group, we
allocated athletes to subgroups: forwards (props, hookers, locks,
flankers, number eights) and backs (scrum halves, fly halves, centers,
wings, full backs). Also, due to diverse physiological demands within
RU (8, 27), athletes were further divided into positional groups
according to their similar movement patterns (8) front five (props,
hookers, locks), back row (flankers, number eights), half backs (scrum
halves, fly halves), centers, and back three (wings and full backs).
Comparisons between positions were not performed for the RL cohort
due to low statistical power when it was subdivided.
Data Analysis
SPSS for Windows version 19 (SPSS, Chicago, IL) software was
used to conduct Pearson’s Chi-square (2) tests to compare genotype
and allelic frequencies between athletes and controls and between
positional subgroups. For ACTN3 and ACE, 26 and 16 tests, respec-
tively, were subjected to Benjamini-Hochberg (BH; 6) corrections to
control false discovery rate, and corrected probability values are
reported. Where appropriate, OR was calculated to estimate effect
size. Alpha was set at 0.05.
RESULTS
All genotype data for athletes and controls were in Hardy-
Weinberg equilibrium. There were no differences in genotype
frequencies within the athlete or control groups according to
nationality. For ACE I/D, there were no differences between all
athletes (RU and RL combined) and controls in genotype (2
1.117, P 0.83), between RU or RL and controls, nor between
playing subgroups for RU (Table 1). Furthermore, for ACTN3
R577X there were no genotype differences between controls
and all athletes (2  1.645, P  0.44), RL (2  1.829, P 
0.44), or RU (2  0.216, P  0.33). However, when we
considered RU playing position, the X allele was overrepresented
in forwards (52.5%) compared with backs [37.8%, 2  8.128,
P 0.02; OR 1.49, 95% confidence interval (CI) 1.13–1.96,
P 0.004] and controls (42%, 2 6.217, P 0.02; OR 1.25,
95% CI  1.02–1.54, P  0.033; Table 1 and Fig. 1A). Simila-
rly, there was a tendency (P 0.023 before BH correction) of the
XX genotype to be overrepresented in forwards (24.8%) com-
pared with backs (15.7%, 2 5.193, P 0.08; OR 1.77, 95%
CI  1.09–2.89, P  0.022) and controls (18.3%, 2  7.582,
P  0.08), with no difference between backs and controls (2 
3.043, P  0.37).
Interestingly, the 69 back three athletes (wings and full-
backs) included only six individuals (8.7%) of XX genotype
that differed from the forwards (24.8%; 2  11.082, P 
0.05; OR 3.46, 95% CI 1.43–8.34, P 0.006) and tended
to differ from the combined half backs and centers group
(19.8%; 2  4.151, P  0.08; OR  2.59, 95% CI 
1.00–6.74, P  0.049). Likewise, the R allele distribution was
greater in the back three (68.8%) than the controls (58.0%;
2  6.672, P  0.02; OR  1.60, 95% CI  1.09–2.33, P 
0.014), forwards (47.5%; 2  11.768, P  0.01; OR  2.00,
95% CI  1.34–2.99, P  0.0007), and the other backs
(58.2%; 2  4.173, P  0.05; OR  1.59, 95% CI 
1.02–2.48, P  0.042) (Fig. 1B).
DISCUSSION
The present study is the first to show a genetic association
with elite athlete status in RU. We found associations for the
ACTN3 R577X polymorphism but not for ACE I/D, thus
rejecting our hypotheses regarding ACE I/D. Furthermore, no
difference was observed for the ACTN3 R577X genotype or
allele distribution between all athletes and controls, thus re-
jecting the hypothesis that differences would exist between
nonathletes and all players as a single cohort. Similarly, there
were no differences between the RU, RL, and control groups
when playing position was not considered. However, as hy-
pothesized, in RU backs compared with forwards there was a
lower proportion of XX genotype and X allele, which probably
reflects the greater need for speed generation in backs and more
sustained activity in forwards. The small cohort of RL athletes
Table 1. Genotype and allele distribution of controls and athletes divided into positional subgroups (for RU only), presented
as genotype/allele counts followed by percentage in parentheses
Genotype All Athletes RL Athletes RU Athletes Controls Forwards Front 5 Back Row Backs Half Backs Centers Back 3
ACE
II 108 (21.4) 18 (21.7) 92 (21.5) 113 (19.8) 49 (20.0) 36 (22.1) 13 (15.9) 43 (23.6) 14 (20.3) 14 (31.1) 15 (22.1)
ID 251 (49.7) 39 (47.0) 214 (50.1) 286 (50.0) 129 (52.7) 86 (52.8) 43 (52.4) 85 (46.7) 33 (47.8) 17 (37.8) 35 (51.5)
DD 146 (28.9) 26 (31.3) 121 (28.3) 172 (30.2) 67 (27.3) 41 (25.2) 26 (31.7) 54 (29.7) 22 (31.9) 14 (31.1) 18 (26.5)
Total 505 83 427 572 245 163 82 182 69 45 68
I allele 467 (46.3) 75 (45.2) 398 (46.6) 512 (44.7) 227 (46.3) 158 (48.5) 69 (42.1) 171 (47.0) 61 (44.2) 45 (50.0) 65 (47.8)
D
allele
543 (53.7) 91 (54.8) 456 (53.4) 630 (55.3) 263 (53.7) 168 (51.5) 95 (57.9) 193 (53.0) 77 (55.8) 45 (50.0) 71 (52.2)
ACTN3
XX 104 (20.5) 15 (18.1) 90 (20.9) 130 (18.3) 61 (24.8) 39 (23.8) 22 (26.8) 29 (15.7) 12 (17.4) 11 (23.4) 6 (8.7)*
RX 234 (46.2) 45 (54.2) 194 (45.0) 337 (47.5) 112 (45.5) 71 (43.3) 41 (50.0) 82 (44.3) 29 (42.0) 22 (46.8) 31 (44.9)
RR 169 (33.3) 23 (27.7) 147 (34.1) 243 (34.2)# 73 (29.7)# 54 (32.9) 19 (23.2) 74 (40.0) 28 (40.6) 14 (29.8) 32 (46.4)
Total 507 83 431 710 246 164 82 185 69 47 69
X
allele
442 (43.5) 75 (45.2) 374 (43.4) 597 (42.0)* 234 (47.6) 149 (45.4) 85 (51.8) 140 (37.8)* 53 (38.4) 44 (46.8) 43 (31.2)
R
allele
572 (56.5) 91 (54.8) 488 (56.6) 823 (58.0)# 258 (52.4) 179 (54.6) 79 (48.2) 230 (62.2) 85 (61.6) 50 (53.2) 95 (68.8)*
RL, rugby league; RU, rugby union. *Different from forwards. #Different from the Back 3.
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means that comparisons between playing positions are not
feasible until the cohort increases substantially.
ACTN3 R577X
The most remarkable finding of the present study was the
low frequency of the XX genotype among the back three RU
athletes (8.7%), approaching, although not as low as, the
frequency observed in elite sprinters (25, 31). The XX geno-
type is present in 18% of Caucasians (Table 1) and indicates
absence of the -actinin-3 protein (3, 24). Absence of -ac-
tinin-3, a protein almost exclusively expressed in fast-twitch
skeletal muscle fibers, could hinder back three (wing and full
back) sprint ability. R allele carriers have a greater proportion
of type II and IIx fibers and larger relative surface area per IIx
fiber than XX carriers (1, 7, 30). Furthermore, Seto et al. (29)
recently showed the likely mechanism for this genotype-phe-
notype association is via the calcineurin muscle fiber remod-
eling pathway. They found greater calcineurin activity (which
induces slow myogenic programming and a shift toward oxi-
dative phenotype) in -actinin-3 knockout mice (KO) and
humans (ACTN3 577XX genotype) due to preferential binding
of -actinin-2 (upregulated in the absence of -actinin-3) to the
fast fiber-specific calsarcin-2 (an inhibitor of calcineurin). This
could explain the advantage of R allele carriers over -actinin-
3-deficient XX individuals for high-velocity contractions, par-
ticularly important for back three RU players. While backs and
forwards previously showed similar fiber type proportions
(19), these older data are arguably not relevant to modern
rugby athletes, given their changed physical characteristics in
recent years (14). Skeletal muscle fiber type proportions are
unknown in contemporary elite RU athletes who now compete
in a more popular, fully professional sport and complete much
higher training loads than previously. Recent in vivo data also
show that R allele carriers exhibit greater muscle volume and
maximal power output (11, 17). While RU forwards show
greater maximal power, backs are able to generate greater
power relative to body mass (W/kg; 9), which corresponds
with the greater R allele frequency in the backs and especially
the back three players. These data, plus evidence that type II
fibers are larger and more powerful per unit volume than type
I (15), suggest the R allele would benefit back three rugby
athletes for muscle power and fast fiber characteristics, which
supports our findings (Table 1 and Fig. 1).
Arguably, the higher propensity for aerobic enzyme activity
(porin, COX IV, hexokinase, citrate synthase, succinate dehy-
drogenase, and 
-hydroxyacyl CoA dehydrogenase; 28, 29)
and greater force recovery after fatigue observed in -actinin-
3-deficient mice (28) could indicate that XX genotype humans
might have a greater capacity for recovery from fatiguing
exercise, a trait that would benefit forwards with their more
sustained match play intensity and necessity for quick recov-
ery. The shorter rest periods for forwards compared with backs
(work-to-rest ratios 1:7.4 and 1:21.8, respectively; 10) indi-
cates that greater fatigue resistance would be particularly
beneficial for forwards. Moreover, the greater calcineurin ac-
tivity in XX homozygote humans and approximately threefold
Fig. 1. ACTN3 allele frequencies. A: allele
frequencies of rugby union (RU) athletes
and controls, with athletes also divided into
playing subgroup (forwards and backs).
#Different from the back 3. B: allele fre-
quencies of RU athletes divided into posi-
tional groups with the addition of the “half
backs and centers combined” group. Statis-
tical analysis between these positional
groups only compared the back 3 with the
half backs and centers combined.
199ACE AND ACTN3 GENE VARIANT FREQUENCY IN ELITE RUGBY ATHLETES
Physiol Genomics • doi:10.1152/physiolgenomics.00107.2015 • www.physiolgenomics.org
increase in calcineurin activity and distance run after endur-
ance training in KO mice (29) further support the notion that
forwards would benefit from a greater fatigue resistance, es-
pecially with exposure to extensive training. These data are
consistent with our observation that forwards exhibit higher
XX genotype and lower R allele frequencies than backs and
controls (Table 1).
When many sports were considered simultaneously, team
sport athlete status showed no association with ACTN3 R577X
genotype (12). However, when one considers the relatively
small number of athletes (205) with mixed status (56.6% elite)
from a range of sports (ice hockey, handball, soccer, etc.), that
is perhaps not surprising. While combining cohorts from dif-
ferent sports can boost sample size and theoretically increase
statistical power, if an association does not exist in all sports,
or even in all athletes within a particular sport due to positional
differences, one would be less likely to detect an association.
The positional differences identified within the present study
demonstrate the value of studying a large sample from a single
sport and, in the absence of detailed physiological data (often
difficult to obtain from large numbers of elite athletes), provide
a viable alternative for future genetic research involving team
sport athletes.
ACE I/D
The current study reports no difference between rugby
athletes and controls or any positional subgroups for ACE I/D.
This lack of association contrasts with a recent meta-analysis
where the ACE I allele was associated with physical perfor-
mance (23). However, Ma et al. (23) also report that special-
ized distance/endurance athletes showed the strongest associ-
ation with the I allele (OR 1.35). Given the mixed metabolic
nature of rugby, a comparable association in the present study
was less likely. Furthermore, the importance of ACE I/D
remains controversial in the literature, with no associations
reported in other isolated team sports such as elite European
soccer (16) and nonelite RU (5). These prior data, in conjunc-
tion with our current findings in a larger study that also
considers playing position, suggest that ACE I/D plays little
role in performance of team sport athletes. ACE I/D genotype-
athlete phenotype associations are more likely to exist in
specialized endurance athletes (26).
Effect Size and Future Applications
OR were calculated to estimate the likelihood that individ-
uals with the advantageous genotype/allele become an elite RU
athlete in a specific position. The ACTN3 XX genotype was
almost twice (OR  1.77) as common in forwards than backs,
which suggests -actinin-3-deficient individuals are more
suited to forward play. Furthermore, forwards were over three
times (OR  3.46) more likely to be XX genotype than the
back three athletes, while the remaining backs (centers and
halves) were over twice as likely to show the -actinin-3-
deficient genotype than the back three (OR 2.59). These data
suggest the ACTN3 R577X polymorphism shows potential to
contribute to position-specific player profiling within RU when
combined with other genetic and physiological data in the
future. In contrast, the ACE I/D polymorphism (OR 1) does
not show equivalent potential in rugby.
While the present cohort size is large compared with previ-
ous single sport genetic analyses, when the cohort was subdi-
vided into playing position, the numbers were reduced so
enlargement of our cohort and replication would be welcome.
Accordingly we continue to recruit elite RU and RL players in
the RugbyGene project and so will steadily become better able
to investigate genetic aspects of specific demands within
rugby. To conclude, the present study revealed position-spe-
cific genetic variation in elite RU athletes for ACTN3 R577X.
The R allele was an advantage for backs, particularly the back
three. Moreover, the current results do not support ACE I/D as
a genetic marker for rugby performance, showing no differ-
ences between athletes and controls or positional subgroups.
This study demonstrates the value of single sport cohorts and
the need for large sample sizes when conducting gene associ-
ation studies in sport. Future objectives of the RugbyGene
project within the broader Athlome project include investigat-
ing whether genetic variants associated with excellence in
other sports are similarly associated in the multifaceted sport of
rugby.
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